AI summary by TwinMind

How We Cured Hepatitis C

Asianometry

21m 54s

Historical Background of Hepatitis

  • Hepatitis = liver inflammation, known since antiquity
  • Sumerian clay tablet 5000 years ago: epidemic jaundice causing death in 11 days
  • Sumerians blamed demon "Aku Kazu"
  • Greeks/Romans reported epidemic jaundice outbreaks
  • American Civil War: 40,000-50,000 cases
  • 1885: Dr. Lerman noticed pattern - jaundice 1-7 months after smallpox vaccine
  • 1942: 56,000 US Navy members infected from contaminated yellow fever vaccine
    • Confirmed infectious agent existence

Classification of Hepatitis Types

  • Split into two categories:
    • Hepatitis A: epidemic version, short incubation, fecal-oral transmission, acute/fatal
    • Hepatitis B: serum version, long incubation, needle/sexual transmission, chronic infection/liver failure/cancer

Discovery of Hepatitis B

  • 1963: Barrack Bloomberg (NIH geneticist) mixed hemophiliac + Australian Aboriginal serums
    • Created red stain, called "Australia antigen"
  • HBS antigen discovery led to first hepatitis B vaccine
  • Bloomberg won Nobel Prize share 1976

Discovery of Hepatitis A

  • October 1973: Stephen Feinstone, Albert Capuchin, Robert Purcell (NIH)
  • Identified virus in stool sample from jaundiced volunteer
  • Published in Science weeks later
  • Tests for both A & B available by 1974

Discovery of Non-A Non-B Hepatitis

  • Despite A & B screening, post-transfusion hepatitis only decreased 20-25%
  • Third form identified: "Non-A Non-B" hepatitis
  • 15-year search for virus (initially thought would be quickly found)
  • More dangerous than initially thought: chronic, causes liver failure/cancer
  • Challenges: no defined antigen, no distinct appearance, wouldn't grow outside body
  • Virus characteristics: 40-60 nanometers, inactivated by chloroform/heat

Early Treatment Attempts

  • Blood screening: elevated ALT (alanine transaminase) levels indicating liver damage
  • 1986 pilot study: interferon therapy showed improvements over 12 months
    • Brought ALT levels to normal with minimal relapses
    • First workable treatment for non-A non-B hepatitis

Breakthrough Discovery at Chiron

  • 1982: Dr. Michael Houghton joined Chiron (California)
  • Methods attempted:
    • Built cDNA library from infected patients/chimps
    • Screened against known virus types (flavavirus, togavirus, HEPA DNA viruses)
    • Tried electron microscopy, cell culture growth
    • Immunofluorescence, immunoelectrophoresis, radio immunoassays
  • Late 1985: immunoscreening approach (against scientific panel advice)
    • Used liver samples from infectious chimpanzee
    • Created cDNA library, inserted into bacteria
    • Screened ~1 million clone proteins against patient antibodies
  • Quin-Lim Choo (Singaporean team member) found 5 positive clones
    • 2 from virus, 2 from chimp genome, 1 unique (labeled "5-1-1")
    • Fragment 5-1-1: 1,500 base pairs, neither human nor chimp
    • Found only in non-A non-B hepatitis samples
  • Led to complete genome sequencing and working antibody test

Hepatitis C Virus Characteristics

  • Size: 65 nanometers wide, flavavirus family
  • Structure: single RNA strand (~9,600 bases) + protein envelope
  • Confused with lipid particles (cholesterol carriers)
  • Very low viral load in humans
  • Only 20% infected show symptoms
  • Targets hepatocytes (liver cells)
  • Key proteins: NS3, 4A, S4B, NS5A, NS5B (essential for replication)
  • High mutation rate: up to 33% difference between variants

Global Impact

  • 130-180 million people infected worldwide (2-3% global population)
  • Highest rates: Middle East, Africa (Egypt, Cameroon), Asia (Pakistan, Taiwan)
  • US: ~3 million infected (most before virus discovery)
  • Transmission: primarily contaminated needles
    • 23% new US infections, 33% deaths from injection drug use
  • 75-85% won't clear virus without treatment
  • 20% develop cirrhosis after 10-15 years
  • 20x higher liver cancer risk
  • Fastest rising cause of cancer deaths in US

Treatment Evolution

Early Treatments (1986-1998)

  • Interferon therapy: <40% cure rate, unpleasant side effects
  • 1998: Added ribavirin (antiviral for hemorrhagic fever viruses)
    • Dual therapy: 40% cure rate (vs 0% interferon alone)
    • Up to 80% cure rates depending on genetic strain
    • Average ~50% effectiveness
    • Adverse effects: rash, anemia, severe infections (40% chance in advanced disease)

Direct Acting Antivirals (DAAs)

  • Concept: target specific viral proteins (like antibiotics for bacteria)
  • Challenge: couldn't grow virus in culture, only infected chimpanzees
  • 2001: New cell cultures and mutant mice introduced
  • Focus on protease inhibitors (successful with HIV)
    • NS3-4A protease: cuts polyprotein into functional pieces
    • Performs 4 of 5 essential cuts

First Generation DAAs (2011)

  • Boceprevir and Telaprevir approved May 2011
  • 65-75% cure rate
  • Issues: HIV co-infection complications, viral resistance (45% population in some areas)
  • Incivek generated $1.6 billion revenue first year

Sofosbuvir Development

  • Originally PSI-7977 by Pharmasset (2010)
  • Named after study group leader Michael Sofia
  • Predecessor PSI-6130: effective in lab, poor oral absorption
  • Solution: prodrug that converts to active ingredient in liver
  • Mechanism: binds NS5B protein, terminates RNA replication chain
  • Effective against multiple genotypes, low toxicity, less resistance

Clinical Success

  • Electron study: 100% effectiveness with ribavirin
  • 2011: Gilead purchased Pharmasset for $11 billion (risky bet - 1/3 Gilead's market value)
  • December 2013: FDA unanimous accelerated approval as breakthrough drug
  • Sovaldi became fastest-selling drug launch at time
  • 2014: $10 billion revenue ($12.5 billion with Harvoni combination)
  • Sales peaked 2015, then declined as patients cured

Recognition and Current Status

  • 2020 Nobel Prize: Michael Houghton, Harvey Alter, Charles Rice
  • Dr. Quin-Lim Choo (original discoverer) not included in Nobel
    • Hong Kong tycoon Li Ka-shing donated monetary sum to him
  • Millions still infected worldwide
  • Price controversy continues
  • Vaccine development remains elusive for complete eradication

TwinMind

Get summaries like this for your own meetings

TwinMind takes notes in the background during meetings, lectures, and calls, then writes the summary for you.

Free plan to get started

No bot joins your calls

Phone, desktop & Chrome apps

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome